News Conference News AHA 2022 Sizeable Minority of Pregnant Women Have CVD, US Data Show Caitlin E. Cox November 11, 2022
News Conference News AHA 2022 Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study Michael O'Riordan November 07, 2022
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News TCT 2022 Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year L.A. McKeown September 23, 2022
News Conference News TCT 2022 Dedicated Catheter for Acute PE Shows Promise in IDE Trial L.A. McKeown September 17, 2022
News Conference News ESC 2022 Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms Yael L. Maxwell August 31, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention Shelley Wood August 27, 2022
News Conference News ESC 2022 First Cardio-Oncology Guidelines From ESC Cover ‘Tremendous’ Territory L.A. McKeown August 26, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022